Everything below concerns MC4 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
=== Stockpiling and sourcing of drugs === A 2017 study found that four U.S. states that allow capital punishment are stockpiling lethal-injection drugs that are in short supply and may be needed for life-saving medical procedures elsewhere. The federal level also involves the stockpiling of lethal-injection drugs, raising questions about their source. At least one alleged supplier, Absolute Standards, is neither registered with the FDA, nor registered as a controlled substances manufacturer with the DEA, and has seen investigations over its alleged involvement.
=== Federal funding === Canada's National Research Council (NRC) provided Providence Therapeutics with CAD$5 million for the launch of January 2021 first phase of PTX-COVID19-B clinical trials. As part of the federal government's "next generation manufacturing supercluster" program, Providence and Northern mRNA had also been "cleared to access up to $5 million" towards the manufacturing start up process, according to a federal government spokesperson. The CBC report in late April 2021 also stated that "it could be eligible for a slice of $113 million in additional funding from the National Research Council of Canada Industrial Research Assistance Program". The federal government had provided funding to some other companies in Canada that were also working to develop a COVID-19 vaccine. Sorenson as Providence Therapeutics CEO posted an open letter to Prime Minister Justin Trudeau, in which he requested $CDN 150 million upfront to be used to pay for clinical trial and material costs. On April 29, 2021, Sorenson appeared before the House of Commons standing committee on international trade, to ask the Minister of Procurement, Anita Anand, to consider PTX-COVID19-B as an alternative to Moderna and Pfizer for the "2022 booster vaccines". Sorenson said that the NRC had approached Providence Therapeutics in 2020 after the company had announced their Phase I trial PTX-COVID19-B. Sorenson told the Standing Committee that, "We've had really good dialogue ever since phase I started. That process has gone on.
In 2008, she co-founded Hepregen, based on her microliver technology for drug testing. Hepregen was acquired by BioIVT in 2018. In 2015, Bhatia spun off Glympse Bio based on her activity-based nanosensor technology. Glympse Bio received significant funding to advance "activity sensors" for diagnosis and therapy selection, completing safety studies in human volunteers before merging with Sunbird Bio in 2023. She has also co-founded other startups, notably Satellite Bio (microliver "satellite" technology with Christopher Chen), Port Therapeutics (along with Gabe Kwong and Mikhail Shapiro), Impilo Therapeutics (with Erkki Ruoslahti, Frank Slack, and Michael Sailor; the company was acquired by Lisata Therapeutics in 2020), Ropirio Therapeutics (with Christopher Chen), Matrisome Bio (with Richard Hynes), and Amplifyer Bio (with J. Christopher Love, Viktor Adalsteinsson, and Todd Golub). Bhatia is a passionate advocate for gender equity and inclusivity in STEM fields. She co-founded the MIT Faculty Founders Initiative with MIT Professor and President Emerita Susan Hockfield and MIT Amgen Professor of Biology Emerita Nancy Hopkins. This initiative aims to address the significant disparity in the number of female academics in science and engineering who become entrepreneurs. Their research revealed that women had founded less than 10% of the 250 biotech startups created by MIT professors, despite women comprising 22% of the MIT faculty. Her dedication to diversity extends to:
Sources: en.wikipedia.org
suborder Clypeasterina family Clypeasteridae L. Agassiz, 1835 family Fossulasteridae Philip & Foster, 1971 † family Scutellinoididae Irwin, 1995 † family Conoclypeidae von Zittel, 1879 † family Faujasiidae Lambert, 1905 † family Oligopygidae Duncan, 1889 † family Plesiolampadidae Lambert, 1905 † suborder Scutellina infraorder Laganiformes family Echinocyamidae Lambert & Thiéry, 1914 family Fibulariidae Gray, 1855 family Laganidae Desor, 1858 infraorder Scutelliformes family Echinarachniidae Lambert in Lambert & Thiéry, 1914 family Eoscutellidae Durham, 1955 † family Protoscutellidae Durham, 1955 † family Rotulidae Gray, 1855 superfamily Scutelloidea Gray, 1825 family Abertellidae Durham, 1955 † family Astriclypeidae Stefanini, 1912 family Dendrasteridae Lambert, 1900 -- Pacific eccentric sand dollar. family Mellitidae Stefanini, 1912 -- Keyhole sand dollars family Monophorasteridae Lahille, 1896 † family Scutasteridae Durham, 1955 † family Scutellidae Gray, 1825 family Taiwanasteridae Wang, 1984 family Scutellinidae Pomel, 1888a † However, the traditional Clypeasteroida is currently not thought to represent a monophyletic group because the Clypeasterina and Scutellina are most likely not each other's closest relatives. Their similarities are possibly the result of convergent evolution. They are part of clade Luminacea, which also includes the orders Cassiduloida and Echinolampadoida. In a recent classification, Clypeasteroida includes only the former Clypeasterina.
Euromac, an EU-funded consortium of medical and research institutes across Europe which is building a patient registry and raising standards of care for people with McArdle Disease. Archived 2021-04-22 at the Wayback Machine International Association for Muscle Glycogen Storage Disease (IamGSD). Walking With McArdle's - IamGSD videos EUROMAC Introduction - Video about McArdle disease and the EUROMAC Registry of McArdle disease and other rare glycogenoses patients
The two substrates of this enzyme are geraniol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are geranial, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is geraniol:NADP+ oxidoreductase.
She also studies antivirals that work through mechanisms other than reverse transcriptase inhibition such as the HIV entry inhibitor maraviroc; she found that genetic variants of CYP3A genes could impact its clearance. Bumpus' lab also found that cytochrome P450 enzymes convert the anti-epileptic valproic acid into byproducts (metabolites) that activate AMPK; they showed that this could reverse the obesity-related problems of fatty liver disease and high blood sugar in mouse models.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.